Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence?
Katsanos
Konstantinos H
KH
Christodoulou
Dimitrios K
DK
Zioga
Aikaterini
A
Tsianos
Epameinondas V
EV
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001379:Azathioprine / Q000009:adverse effects; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D009508:Nevus, Pigmented / Q000139:chemically induced*; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D001379:Azathioprine